TherapeuticsMD, Inc. 8-K

Exhibit 99.1





TherapeuticsMD Announces Second Quarter 2019 Financial Results


-IMVEXXY® Net Revenue $3.1 Million for the Second Quarter of 2019-

-Total Net Revenue for the Second Quarter of 2019 Above Guidance at $6.1 Million-

-Company Raises Full-Year Net Revenue Guidance to Range of $29.45 Million to $34.20 Million-

-Conference Call Scheduled for 4:30 p.m. ET Today-


BOCA RATON, Fla. August 6, 2019 – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the second quarter ended June 30, 2019 and provided a business update.


“We are pleased to report a solid quarter that came in ahead of our expectations and believe the next few quarters will be transformative,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “As we move into the second half of the year, we plan to conduct pre-launch activities for ANNOVERA and continue to expand market access for our menopause portfolio. We expect IMVEXXY and BIJUVA® to have extensive coverage for commercially insured lives by the end of the year. We are pursuing preferred status for IMVEXXY on Medicare Part D plans and expect coverage decisions by the fourth quarter, which is significant given the higher proportion of IMVEXXY Medicare Part D business.”


Second Quarter and Recent Developments

IMVEXXY (estradiol vaginal inserts) prescription growth continues as highlighted by a record month in July 2019 with approximately 45,500 prescriptions dispensed and paid for by patients. Approximately 106,000 prescriptions of IMVEXXY were dispensed and paid for by patients during the second quarter of 2019. This is an increase of approximately 41% in prescription volume for the second quarter of 2019 as compared to the first quarter of 2019. Strong refill rates continue to indicate that women are having a positive experience with IMVEXXY.
IMVEXXY currently has unrestricted access with seven of the top commercial payers of VVA products and two of the top Medicare Part D payers of VVA products. The company expects additional coverage decisions by the top commercial and Medicare Part D payers of VVA products during the third and fourth quarters of 2019.
The commercial launch of BIJUVA (estradiol and progesterone capsules) commenced on April 17, 2019 and approximately 8,900 prescriptions have been dispensed and paid for by patients through July 31, 2019.
BIJUVA currently has unrestricted access with four of the top ten commercial payers. This includes two new plans, United Healthcare and OptumRX, that began adjudicating BIJUVA on August 1, 2019.
Pre-launch activities have commenced for ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system). The company plans to continue discussions with the U.S. Food and Drug Administration (FDA) on the potential for ANNOVERA to be designated a new, 19th method of contraception, and begin discussions with payers with a full-scale launch planned for the first quarter of 2020.
The company recently closed an exclusive license and supply transaction with Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA and IMVEXXY outside of the United States. On August 5, 2019, the company received an upfront payment under this agreement of approximately $15.4 million and is eligible to receive additional regulatory and sales milestone payments, as well as a royalty on net sales.





Summary of Second Quarter 2019 Financial Results

Total net revenues for the second quarter of 2019 increased 62%, to approximately $6.1 million, compared with net revenues of approximately $3.8 million for the prior year’s quarter. The increase was primarily due to sales of approximately $3.1 million of IMVEXXY and $134,000 of BIJUVA in the second quarter of 2019, partially offset by a decrease in the company’s prescription prenatal vitamin business of approximately $940,000 from the comparable quarter in 2018.

Net revenues have been greatly affected by the company’s co-pay assistance programs introduced to launch IMVEXXY and BIJUVA, which allowed eligible enrolled patients to access the products at a reasonable cost of no more than $35 per prescription regardless of insurance coverage. The company expects revenues related to IMVEXXY and BIJUVA will improve as commercial and Medicare Part D payer coverage increases, and plans complete the process needed to adjudicate prescriptions at pharmacies.

Research and development (R&D) expenses for the second quarter of 2019 decreased to approximately $5.0 million, compared with approximately $6.8 million for the prior year’s quarter. R&D costs decreased primarily as a result of transferring certain costs and activities from R&D expenses to support commercial and launch efforts after the FDA approval of IMVEXXY and BIJUVA. R&D expenses include costs related to manufacturing validation as well as pre-clinical work to support the company’s R&D activities.


Sales, general and administrative (SG&A) expenses increased for the second quarter of 2019 to approximately $41.4 million, compared with approximately $29.5 million for the prior year’s quarter. The increase in second quarter 2019 SG&A expenses was primarily a result of increased expenses associated with sales and marketing efforts and personnel costs to support the launch and commercialization of IMVEXXY and BIJUVA, including costs related to sales force expansion, outsourced sales personnel and their related expenses, physician education and product samples, and other expenses related to product commercialization. The company expects sales and marketing expenses to continue to increase as it continues the launch of BIJUVA, prepares for the launch of ANNOVERA, and continues to support its growing business and commercialization of its products.


During the second quarter of 2019, the company took a one-time charge for extinguishment of debt of approximately $10.1 million in connection with the refinancing of its term loan. As a result of the foregoing, net loss increased to approximately $55.2 million, or $0.23 per basic and diluted share, for the second quarter of 2019. Excluding the one-time charge for extinguishment of debt, the net loss for the second quarter was approximately $45.2 million, or $0.19 per basic and diluted share, compared with approximately $33.2 million, or $0.15 per basic and diluted share, for the second quarter of 2018.


Balance Sheet

As of June 30, 2019, the company’s cash on hand totaled approximately $182.8 million, compared with approximately $161.6 million at December 31, 2018. Total outstanding debt, net of issuance costs, was approximately $194.1 million as of June 30, 2019.



Financial Guidance

The following table outlines TherapeuticsMD’s revised 2019 financial guidance (in millions).


  3Q 2019 4Q 2019 FY 2019
  Original Revised Original Revised Original Revised
FDA-Approved Products $4.50-$6.50 Unchanged $11.00-$13.00 Unchanged $20.00-$24.5 $20.75-$24.75
Prescription Prenatal Vitamins $1.75-$2.25 $2.25-$2.50 $1.50-$2.00 $1.75-$2.25 $7.15-$8.65 $8.70-$9.45
Total Net Revenues $6.25-$8.75 $6.75-$9.00 $12.50-$15.00 $12.75-$15.25 $27.10-$33.10 $29.45-$34.20


Conference Call and Webcast Details


TherapeuticsMD will host a conference call and audio webcast today at 4:30 p.m. ET to discuss these financial results and provide a business update.


Date:   Tuesday, August 6, 2019
Time:   4:30 p.m. ET
Telephone Access (US):   866-665-9531
Telephone Access (International):   724-987-6977
Access Code for All Callers:   1392883

A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the TherapeuticsMD website at Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call's completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 1392883.

Please see the Full Prescribing Information, including indication and Boxed WARNING, for each TherapeuticsMD product as follows:

IMVEXXY (estradiol vaginal inserts) at
BIJUVA (estradiol and progesterone capsules) at
ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) at

About TherapeuticsMD, Inc.


TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.






Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA, BIJUVA® and its hormone therapy drug candidates and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website:

Investor Contact

Nichol Ochsner

Vice President, Investor Relations

561-961-1900, ext. 2088








   June 30, 2019  December 31, 2018
Current Assets:          
Cash  $182,846,301   $161,613,077 
Accounts receivable, net of allowance for doubtful accounts of $764,102 and $596,602, respectively   18,383,012    11,063,821 
Inventory   7,494,440    3,267,670 
Other current assets   7,739,048    10,834,693 
     Total current assets   216,462,801    186,779,261 
Fixed assets, net   1,432,137    472,683 
Other Assets:          
License rights   20,000,000    20,000,000 
Intangible assets, net   4,688,114    4,092,679 
Other assets   3,635,227    324,855 
Security deposit   334,866    314,446 
     Total other assets   28,658,207    24,731,980 
       Total assets  $246,553,145   $211,983,924 
Current Liabilities:          
Accounts payable  $19,499,238   $22,743,841 
Other current liabilities   22,376,617    18,334,948 
     Total current liabilities   41,875,855    41,078,789 
Long-Term Liabilities:          
Long-term debt   194,095,220    73,381,014 
Operating lease liability   2,488,101    —   
       Total liabilities   238,459,176    114,459,803 
Commitments and Contingencies          
Stockholders' Equity:          
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding   —      —   
Common stock - par value $0.001; 350,000,000 shares authorized: 241,221,840 and 240,462,439 issued and outstanding, respectively   241,222    240,463 
Additional paid-in capital   621,871,919    616,559,938 
Accumulated deficit   (614,019,172)   (519,276,280)
     Total stockholders' equity   8,093,969    97,524,121 
       Total liabilities and stockholders' equity  $246,553,145   $211,983,924 









   Three Months Ended  Six Months Ended
   June 30,  June 30,
   2019  2018  2019  2018
Revenues, net  $6,078,865   $3,763,010   $10,025,516   $7,536,402 
Cost of goods sold   1,248,860    454,161    2,011,687    1,087,784 
Gross profit   4,830,005    3,308,849    8,013,829    6,448,618 
Operating expenses:                    
Sales, general, and administrative   41,387,451    29,466,770    76,251,533    50,224,007 
Research and development   4,964,368    6,798,380    11,282,250    13,837,677 
Depreciation and amortization   115,059    65,603    221,997    125,224 
     Total operating expenses   46,466,878    36,330,753    87,755,780    64,186,908 
Operating loss   (41,636,873)   (33,021,904)   (79,741,951)   (57,738,290)
Other (expense) income                    
Loss on extinguishment of debt   (10,057,632)   —      (10,057,632)   —   
Miscellaneous income   486,597    334,238    1,175,318    648,795 
Interest expense   (4,028,609)   (531,382)   (6,118,627)   (531,382)
     Total other (expense) income   (13,599,644)   (197,144)   (15,000,941)   117,413 
Loss before income taxes   (55,236,517)   (33,219,048)   (94,742,892)   (57,620,877)
Provision for income taxes   —      —      —      —   
Net loss  $(55,236,517)  $(33,219,048)  $(94,742,892)  $(57,620,877)
Loss per share, basic and diluted:                    
Net loss per share, basic and diluted  $(0.23)  $(0.15)  $(0.39)  $(0.27)
Weighted average number of common shares outstanding, basic and diluted   241,221,840    216,640,186    241,114,532    216,583,067 










   Six Months Ended
   June 30,
   2019  2018
Net loss  $(94,742,892)  $(57,620,877)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation of fixed assets   133,049    79,201 
Amortization of intangible assets   88,948    46,023 
Write off of patent and trademark cost   78,864    —   
Non-cash operating lease expense   443,734    —   
Provision for doubtful accounts   167,500    38,024 
Loss on extinguishment of debt   10,057,632    —   
Share-based compensation   5,224,212    4,128,440 
Amortization of deferred financing fees   316,880    30,155 
Changes in operating assets and liabilities:          
Accounts receivable   (7,486,691)   (1,335,209)
Inventory   (4,226,770)   (395,219)
Other current assets   1,710,697    2,539,394 
Accounts payable   (3,244,603)   7,329,560 
Accrued expenses and other liabilities   2,801,717    561,615 
Net cash used in operating activities   (88,677,723)   (44,598,893)
Patent costs   (763,247)   (434,677)
Purchase of fixed assets   (1,092,504)   (45,720)
Payment of security deposit   (20,420)   (11,486)
Net cash used in investing activities   (1,876,171)   (491,883)
Proceeds from exercise of options and warrants   100,107    1,128,996 
Repayment of the Credit Agreement   (81,660,719)   —   
Proceeds from the Financing Agreement   200,000,000    75,000,000 
Payment of deferred financing fees   (6,652,270)   (3,786,918)
Net cash provided by financing activities   111,787,118    72,342,078 
Increase in cash   21,233,224    27,251,302 
Cash, beginning of period   161,613,077    127,135,628 
Cash, end of period  $182,846,301   $154,386,930 
Cash paid for interest  $6,989,570   $—   
Cash paid for income taxes  $—     $—   



The following information was filed by Therapeuticsmd, Inc. (TXMD) on Tuesday, August 6, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Therapeuticsmd, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Therapeuticsmd, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019) Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019) Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account